GI Oncology
Conference Coverage
Imatinib rechallenge improves PFS in GIST, but not for long
Major finding: Progression-free survival of patients with advanced GIST was 1.8 months following imatinib rechallenge, compared with 0.9 months...
Conference Coverage
Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer
Major finding: Median overall survival was 7.9 months for gemcitabine and capecitabine alone, 6.9 months for gemcitabine and capecitabine followed...
News
EET and esophagectomy yield similar cancer-free survival
Major finding: No significant differences were seen between the groups with respect to 2-year esophageal cancer-free survival (93.5% and 89.6% in...
News
Urinary test shows promise for pancreatic cancer detection
Major finding: A novel urinary test has 85% sensitivity and 91% specificity for distinguishing pancreatic cancer and chronic pancreatitis.Data...
News
Rates of adjuvant therapy for pancreatic cancer still low
Major finding: The use of surgery alone as first course treatment for stage II pancreatic cancer decreased by nearly 25% at teaching and community...
Conference Coverage
FIRE-3: Cetuximab/FOLFIRI prolongs metastatic colorectal cancer survival
Major finding: Median overall survival with cetuximab plus FOLFIRI was 28.7 months vs.
News
Tumor biology appears to play role in missed interval colorectal cancers
Major finding: At 6-36 months after colonoscopy the rate of missed interval cancers was 3.5%; at 6-60 months the rate was 6%.Data source: A...
News
Reflux after surgery increases risk of esophageal cancer
Major finding: Patients with recurrent reflux after surgical treatment are three times more likely to develop an esophageal adenocarcinoma than...
News
Radical resection trumps local excision in stage I CRC
Major Finding: Five-year overall survival in patients with stage I colorectal carcinoma treated via local excision was 68.4% compared to 75.2%...
News
Adjuvant therapy selection in gastric cancer still more art than science
News
New blood test could identify early pancreatic cancer
Major finding: A serum panel of four metabolites had a 78% sensitivity for detecting resectable pancreatic cancers.Data source: The panel was...